5 completed, 1 active not recruiting, 1 unknown, 1 withdrawn. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 5, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Dermatitis, Contact: new trials by email Literature Review of Dermatitis, Contact trials Research Report on Dermatitis, Contact
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab - Skin Inflammation, Allergic Contact Dermatitis | Phase 2 / Phase 3 | Active not recruiting | Wei-Che Ko | 45 | 2022-11-15 | 2026-06-09 |
| The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis Anakinra, Sodium Chloride 9mg/ml Injection - Allergic Contact Dermatitis | Phase 3 | Completed | Herlev and Gentofte Hospital | 20 | 2022-10-11 | 2025-05-20 |
| Comparing Tissue Adhesives in Port Site Closure Dermabond (2-Octylcyanoacrylate), Swiftset (N-butyl-2-cyanoacrylate), Liquiband (2-Octylcyanoacrylate) - Dermatitis, Contact | Phase 3 | Completed | The University of Texas Health Science Center, Houston | 180 | 2022-06-29 | 2026-06-26 |
| Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects Butenafine HCl 1% (BAY1896425) - Dermatitis, Phototoxic | Phase 3 | Completed | Bayer | 32 | 2013-06-24 | 2020-11-13 |
| Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants Butenafine HCl 1% (BAY1896425) - Induction Phase, Butenafine HCl 1% (BAY1896425) - Challenge Phase - Dermatitis, Photoallergic | Phase 3 | Completed | Bayer | 137 | 2013-06-10 | 2020-11-16 |
| Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents Patch Test - Contact Dermatitis | Phase 3 | Withdrawn | Allerderm | 2012-12-01 | 2013-02-27 | |
| Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis 0.5% prednisolone acetate cream, 0.1% betamethasone valerate cream - Dermatitis, Atopic, Dermatitis, Contact | Phase 3 | Unknown | Mantecorp Industria Quimica e Farmaceutica Ltd. | 170 | 2010-02-01 | 2009-11-11 |
| Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens - Contact Dermatitis | Phase 3 | Completed | Allerderm | 235 | 2008-04-01 | 2020-05-05 |
Dermatitis (2) · Dermatitis, Allergic Contact (2) · Dermatitis, Atopic (1) · Dermatitis, Photoallergic (1) · Dermatitis, Phototoxic (1) · Dermatitis, Seborrheic (1) · Hypersensitivity (1) · Psoriasis (1)
Skin Diseases (8) · Skin Diseases, Eczematous (8) · Skin and Connective Tissue Diseases (8) · Dermatitis (6) · Immune System Diseases (5) · Hypersensitivity (4) · Hypersensitivity, Delayed (3) · Photosensitivity Disorders (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Dermatitis, Allergic Contact (1) · Dermatitis, Irritant (1) · Genetic Diseases, Inborn (1) · Hypersensitivity, Immediate (1) · Sebaceous Gland Diseases (1)
butenafine (2) · Adalimumab (1) · Betamethasone Valerate (1) · Fluticasone (1) · Interleukin 1 Receptor Antagonist Protein (1) · Patch Tests (1) · Sodium Chloride (1) · Triamcinolone Acetonide (1) · Ustekinumab (1) · canakinumab (1) · dupilumab (1) · guselkumab (1) · sarilumab (1) · squaric acid dibutyl ester (1)
Allerderm (2) · Bayer (2) · Herlev and Gentofte Hospital (1) · Mantecorp Industria Quimica e Farmaceutica Ltd. (1) · The University of Texas Health Science Center, Houston (1) · Wei-Che Ko (1)
United States (6) · Denmark (2)
Joseph Fowler, MD (2) · Adilson Costa, MD (1) · Cory Dunnick, MD (1) · Donald V Belsito, MD (1) · Evy Paulsen, M.D., Ph.D (1) · Jerri Hoskyn, MD (1) · Luz Fonacier, MD (1) · Roberta F. J. Criado, MD (1) · Sandy Skotnicki-Grant, MD (1) · Wei-Che Ko, MD (1)
2008 (1)